X70 Stock Overview
A clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Panbela Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.45 |
| 52 Week High | US$0.63 |
| 52 Week Low | US$0.38 |
| Beta | 0.90 |
| 11 Month Change | 0.90% |
| 3 Month Change | -26.23% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -23.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| X70 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -1.8% | -0.1% |
| 1Y | n/a | -18.5% | 2.4% |
Return vs Industry: Insufficient data to determine how X70 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how X70 performed against the German Market.
Price Volatility
| X70 volatility | |
|---|---|
| X70 Average Weekly Movement | 7.4% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: X70's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine X70's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 8 | Jennifer Simpson | www.panbela.com |
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin.
Panbela Therapeutics, Inc. Fundamentals Summary
| X70 fundamental statistics | |
|---|---|
| Market cap | €1.81m |
| Earnings (TTM) | -€33.91m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs X70 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X70 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$36.41m |
| Earnings | -US$36.41m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -7.50 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -131.6% |
How did X70 perform over the long term?
See historical performance and comparison